Latest Industry Insights
Industry Insight
Advancing ALS Research With Omics Analysis Technology
Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.
Industry Insight
Antibody To Treat Lung Inflammation May Offer Potential in COVID-19
Early stage biotech company Aqualung Therapeutics is currently developing a therapeutic monoclonal antibody – ALT-100 – for the treatment of unchecked inflammation. COVID-19 can cause severe pneumonia and respiratory failure. There is therefore a potential option to treat patients diagnosed with COVID-19 with ALT-100. Technology Networks recently spoke with Joe Garcia, MD, Founder and Chief Executive Officer of Aqualung Therapeutics to learn more.
Industry Insight
Development of Immunotherapy To Treat COVID-19 in Progress
CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.
Industry Insight
A New System for DNA/RNA Delivery in Cancer Therapeutics
Cancer immunotherapies and viral vaccines that are nucleic acid-based can be challenging to formulate and require highly specific delivery systems. Commonly adopted delivery systems, such as lipid nanoparticles and viral vectors, can have limitations, therefore alternative approaches are being developed. Technology Networks recently spoke with Nigel Theobald, CEO and Founder of N4 Pharma, to learn more about nanoparticle drug delivery, the Nuvec® platform and its progress towards clinical trials.
Industry Insight
Targeting the Vaginal Microbiome for Urogenital and Reproductive Health
Technology Networks recently spoke with Dr Jacques Ravel (Chief Scientist of LUCA Biologics) and Luba Greenwood (CEO of LUCA Biologics) to learn more about what the vaginal microbiome is, how it can contribute to human pathology and the development of novel therapeutics in this space that are approaching clinical trials.
Industry Insight
Investigating the Medical Potential of Cannabis-derived Products
We recently had the pleasure of speaking with William Levine, D.D.S., CannRx Founder and Chief Scientific Officer. Levine discusses CannRx’s mission to develop transformative, scientifically based, proprietary cannabis technologies, highlights some of the medical applications of cannabis-derived products, and explains why it is so important to analyze the various active compounds in cannabis.
Industry Insight
Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders
Technology Networks recently had the pleasure of speaking with Bruce Steel, CEO Equillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.
Industry Insight
Different by Design: The Impact of Drug Delivery Device Design on the Future of the Biosimilars Market
The pharmaceutical market is in a period of transition as the introduction of new biosimilars increases. Here, George I'ons, Owen Mumford Pharmaceutical Services, explores a lesser known but albeit important factor influencing the success of this transitional period is delivery device design of such drugs.
Industry Insight
Yeast, A "Rising" Approach to Manufacturing Collagen
Technology Networks spoke with Jonathan Widdowson, Director of ProColl and Enterprise Fellow at the Royal Academy of Engineering Enterprise Hub, to learn more about how yeast can be used to manufacture collagens and the applications of this approach.
Industry Insight
The Power of Positrons
Over the last five to ten years, multi-modal imaging has become established as a significant component of a preclinical researcher’s analytical toolbox. Here, we highlight perhaps the most used and certainly the most sensitive and quantitative of these imaging modalities, the combination of positron emission tomography (PET) with X-ray computed tomography (CT), or PET/CT.
Advertisement